SAN FRANCISCO--(BUSINESS WIRE)--Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including bone, muscle and red blood cells, today announced that it has designated a new development candidate, ACE-536, which selectively increases red blood cells and hemoglobin, as a potential treatment for anemia. ACE-536, like the Company’s lead development candidate ACE-011, utilizes a mechanism fundamentally different from existing therapies to increase hemoglobin levels.
